Fierce Biotech

J&J buys into Halda's cell death tech with $3B acquisition, beefing up prostate cancer pipeline

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

J&J expands cancer portfolio with $3.05 billion Halda buy

Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand ...
BioSpace

J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...
NJBIZ

J&J to acquire Connecticut biotech in $3.05B oncology deal

J&J will acquire Halda Therapeutics in a $3.05B deal, adding prostate cancer therapy HLD-0915 and expanding its oncology ...
BioPharma Dive

J&J adds to pharma’s M&A spree with $3B buyout of startup Halda

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...
pharmaphorum

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and ...

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Vida Ventures ("Vida"), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio ...